Compare BridgeBio Pharma Inc (BBIO) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Google Inc — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Google Inc trades at $355.22 (market cap $4.37T). The key difference: Google Inc is far larger — about 265.5× BridgeBio Pharma Inc's market cap, and Google Inc pays a 0.25% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GOOG | |
|---|---|---|
Market Cap | $16.46B | $4.37T |
Sector | Health | Technology |
52-Week High | $90.17 | $399.06 |
52-Week Low | $44.81 | $183.10 |
Enterprise Value | $18.02B | $4.34T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Alphabet (GOOG) trades at $350.67, down 1.23% amid bearish technical signals, though fundamentals remain robust with strong earnings beats and 32.8% net margin. Revenue grew to $402.84B in 2025, while analyst consensus is overwhelmingly bullish with an 86.84% buy rating and $457.50 price target. Recent news highlights AI advancements and regulatory scrutiny.
Outlook is positive given earnings momentum and AI leadership, but risks include regulatory probes and high valuation multiples. The stock offers growth potential with disciplined risk management advised amid technical weakness and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
